Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Concepts and definitions · Clinical evaluation report

The Clinical Evaluation Report Under the EU Medical Device Regulation (MDR)

A clinical evaluation report is required by Article 61 and Annex XIV Part A of Regulation (EU) 2017/745, which has applied since May 2021. It records a continuous process, for which the clinical evaluation plan is prepared first.

Pubrica AcademyWritten by a research writing specialist Reviewed bya research methodology reviewer Published15 October 2026 Last checked15 October 2026 Reading time12 minutes Sources7 primary

A clinical evaluation report is the documented output of the clinical evaluation that a medical device manufacturer must carry out under EU law: an appraisal of all the clinical evidence for one device against its intended purpose and claimed benefits. It is required by Article 61 of Regulation (EU) 2017/745 and by Part A of its Annex XIV, and it is maintained continuously rather than written once.

Definition of a clinical evaluation report

Clinical evaluation is a process, and the report is its record. MDCG guidance describes the obligation as one where “clinical evaluation is a process where this qualified assessment has to be done on a continuous basis”2, which is the single most important thing to understand about the document: it is not a submission artefact produced once and filed, but a live assessment updated as evidence accumulates and as post-market data arrive.

The process begins with “the identification of available clinical data”2 — literature, the manufacturer’s own clinical investigations, equivalent-device data where an equivalence claim is justified, and post-market clinical follow-up — and proceeds to a qualified appraisal of whether that evidence supports the device’s intended purpose and claimed benefits.

One term worth flagging, because authors reach for it as though it were defined: MDCG 2020-6 states plainly that “'Sufficient clinical evidence' is not defined in the MDR.”2 So "sufficient clinical evidence" is a judgement to be argued, device by device, not a threshold to be met.

Governing regulation

The regulation is Regulation (EU) 2017/745, adopted 5 April 2017, in force from 26 May 2018 and applying since 26 May 20211. It repealed the two earlier directives — the European Medicines Agency recorded at the time that “The MDR replaces the existing Directives for medical devices (93/42/EEC and 90/385/EEC)”1.

That date matters for how this subject is written about. Guidance that describes the MDR as forthcoming, or that anchors compliance risk to the Directive, is describing a position that ended more than four years ago.

The provisions. Article 61 is the clinical evaluation article, and it requires that “manufacturers shall plan, conduct and document a clinical evaluation in accordance with this Article” — “in accordance with this Article and Part A of Annex XIV”2

A sourcing note, because it affects what this page can responsibly quote. The text of Annex XIV itself was not reachable: EUR-Lex's full text is closed to automated retrieval and the mirrors available truncate before the annexes. So the annex provisions on this page are cited through the MDCG documents that quote them, and no wording is attributed to the annex directly. If you are drafting against Annex XIV, work from the regulation itself.

Priority of the clinical evaluation plan

The live version of this page never mentioned the clinical evaluation plan, which makes the report impossible to understand: the plan is what the report reports against.

Annex XIV Part A Section 1(a) is the plan provision. MDCG 2020-6 heads that requirement “Annex XIV Part A Section 1a: Establish or update a clinical evaluation plan” and states that “Manufacturers are required to document a clinical evaluation plan to meet the requirements of MDR Annex XIV Section 1a.”2 The two documents work together: “clinical evaluation plans and reports need to be produced and updated”2

What the plan has to contain. The clearest public statement of this is the assessment template a notified body uses, which tells the assessor to “confirm that it meets the requirements of Annex XIV Part A Section 1a”3. Reading it backwards gives the author’s checklist:

  • The general safety and performance requirements that need clinical data support.
  • The intended purpose, target groups, indications and contraindications.
  • The intended clinical benefits, with clinical outcome parameters.
  • The methods for assessing clinical safety, including residual risks and side effects.
  • The parameters for benefit-risk acceptability, based on the state of the art.
  • A clinical development plan from exploratory to confirmatory studies, with post-market clinical follow-up, milestones and acceptance criteria.

Note the last of those. A clinical development plan running from exploratory to confirmatory investigations, with post-market clinical follow-up, milestones and acceptance criteria, is part of the plan — which means the evidence strategy is committed to in advance rather than reconstructed afterwards from whatever was found3.

Distinction between a CER and a clinical study report

These two are routinely conflated, and the live version of this page did so. They are different documents in different regulatory systems.

Table 1. Clinical evaluation report and clinical study report compared

Clinical evaluation report (CER)Clinical study report (CSR)
What it isA device regulatory document: the output of the clinical evaluation process, summarising and appraising all the clinical evidence for one device.A report of one clinical trial.
Governing regulationMDR Article 61 and Annex XIV Part A, with MDCG guidance.ICH E3, Structure and Content of Clinical Study Reports.
ScopeAll available clinical data for the device, including literature, the manufacturer's own investigations, and post-market data.One study: its protocol, conduct, population, results and conclusions.
How often it is producedContinuously updated through the device's life, alongside the clinical evaluation plan.Once per study, at its conclusion.
SectorMedical devices, in the EU.Medicines and devices, internationally, wherever ICH applies.

The clinical study report has its own guideline: ICH E3, whose stated objective is “to facilitate the compilation of a single core clinical study report acceptable to all regulatory authorities of the ICH regions”6 It covers one study, in sixteen numbered sections. A CER may well cite several clinical study reports among its evidence — which is the relationship between them, and the reason the confusion arises.

Current status of MEDDEV 2.7/1 rev. 4

This is the question most often got wrong, in both directions: some guidance presents MEDDEV 2.7/1 rev. 4 as the current authority, and some treats it as withdrawn. Neither is right.

Current status

MEDDEV 2.7/1 rev. 4 was written under the Directives. Under the MDR it is neither current standalone guidance nor formally withdrawn: MDCG 2020-6 carries an appendix listing the sections of it still considered relevant, and states that only the text of the MDR is authentic in law. One of its sections is flagged in MDCG 2020-6 as referring to the Directive where the MDR requirement should be used instead. It is therefore a source to be consulted through that appendix rather than a document to be worked from directly. Its full title and publication date could not be confirmed from an official copy and are not given here.

MDCG 2020-6 introduces its appendix on the point by saying that “The identified sections of MEDDEV 2.7/1 rev. 4 are considered relevant to MDR as they” “contain helpful information regarding how to perform activities associated with clinical evaluation”2 — and sets the limit in the same document: “However only the text of the MDR is authentic in law, sections relevant to the MDR are listed in Appendix I”2

The Commission’s own index of guidance lists no MEDDEV document as a standalone entry5, which is consistent with that reading.

Applicable MDCG guidance

The Medical Device Coordination Group publishes the working guidance. These are the documents bearing on clinical evaluation:

Table 2. MDCG guidance relevant to clinical evaluation

DocumentDateWhat it covers
MDCG 2020-5April 2020Clinical evaluation — equivalence. A guide for manufacturers and notified bodies.
MDCG 2020-6April 2020Clinical evidence needed for devices previously CE marked under the Directives. Carries the appendix on MEDDEV 2.7/1 rev. 4.
MDCG 2020-13July 2020Clinical evaluation assessment report template.
MDCG 2020-1March 2020Clinical evaluation and performance evaluation of medical device software.
MDCG 2020-7 and 2020-8April 2020Post-market clinical follow-up plan and evaluation report templates.
MDCG 2023-7December 2023Exemptions from clinical investigations under Article 61(4) to (6), and sufficient access to data for an equivalence claim.
MDCG 2024-10June 2024Clinical evaluation of orphan medical devices.
MDCG 2024-5April 2024Content of the Investigator's Brochure for a device clinical investigation.

Two notes on citing these. MDCG 2020-5 states that it is an MDCG document established under Article 103 of the MDR and is not a European Commission document4, which is worth reproducing accurately if you cite it. And the Commission’s index labels MDCG 2020-6 differently from the title on the document’s own front page5; cite the document’s title.

Requirements outside the European Union

There is no US equivalent called a clinical evaluation report. The comparable requirement is the valid scientific evidence standard at 21 CFR 860.7, applied through the clinical data and analysis sections of a premarket approval application under 21 CFR 814.20.7 The FDA's own framing of the evidence standard is that effectiveness evidence “shall consist principally of well-controlled investigations”7, and that “isolated case reports, random experience and unsubstantiated opinions” do not constitute valid scientific evidence7.

The practical consequence for a manufacturer filing in both regions: the underlying clinical evidence is the same body of work, but the document that presents it is not interchangeable. A CER is not a PMA clinical section, and neither is a translation of the other.

Preparation of a clinical evaluation report

Practical application

  1. The clinical evaluation plan should be written first, against Annex XIV Part A Section 1(a), and agreed before the evaluation begins; the report documents the evaluation against the plan.
  2. The annex requirements should be taken from the regulation itself, with MDCG guidance used to determine how to meet them.
  3. MEDDEV 2.7/1 rev. 4 should be treated as accessible only through the appendix to MDCG 2020-6, and each section relied upon should be checked against the MDR text, which is the only text authentic in law.
  4. Where equivalence is claimed, MDCG 2020-5 and MDCG 2023-7 should be consulted before drafting, because the access-to-data requirement determines whether the claim is available at all.
  5. The report should be maintained as a live document, updated as post-market clinical follow-up data become available rather than archived after certification.
  6. “Sufficient clinical evidence” should not be described as a defined threshold. MDCG 2020-6 states that it is not defined in the MDR, so it must be justified for the specific device.
  7. The CER and any clinical study reports should be kept distinct in the documentation plan. A CSR reports one study against ICH E3; the CER appraises all the clinical evidence.

Key points

A clinical evaluation report is the record of a continuous process required by Article 61 and Annex XIV Part A of Regulation (EU) 2017/745, which has applied since 26 May 2021. The clinical evaluation plan is prepared first, and the report reports against it. A CER is not a clinical study report, which covers a single trial and is governed by ICH E3. MEDDEV 2.7/1 rev. 4 is neither current nor withdrawn: only the sections listed in the appendix to MDCG 2020-6 are considered relevant, and only the MDR text is authentic in law. No US document bears this name; the comparable standard is valid scientific evidence under 21 CFR 860.7.

The documented output of the clinical evaluation process required of a medical device manufacturer in the EU: a systematic appraisal of all the clinical evidence for one device, against that device’s intended purpose and claimed benefits. It is required by Article 61 of Regulation (EU) 2017/745 and Part A of its Annex XIV, and it is maintained continuously rather than written once.

Regulation (EU) 2017/745, the Medical Device Regulation, which was adopted on 5 April 2017, entered into force on 26 May 2018 and has applied since 26 May 2021. It repealed the two earlier directives, 93/42/EEC and 90/385/EEC. Article 61 is the clinical evaluation article; Annex XIV Part A sets out what the evaluation has to cover.

The clinical evaluation plan comes first and governs what the evaluation will do; the report documents what it found. The plan is required by Annex XIV Part A Section 1(a), and MDCG guidance describes the pair as documents that need to be produced and updated together, because clinical evaluation is a continuous process rather than a one-off exercise.

No, and conflating them is a common and consequential error. A clinical study report covers one trial and is governed by ICH E3. A clinical evaluation report covers all the clinical evidence for one device — published literature, the manufacturer’s own investigations and post-market data — and is governed by the MDR. The two documents differ in scope, sector and governing authority.

Only through MDCG 2020-6, and with caution. That guidance carries an appendix listing the sections of MEDDEV 2.7/1 rev. 4 still considered relevant under the MDR, and states that only the text of the MDR is authentic in law. It also flags at least one section as referring to the Directive where the MDR requirement should be used instead. It is therefore a source to be consulted through that appendix rather than a document to be worked from directly.

Not under that name. There is no FDA document called a clinical evaluation report. The comparable requirement is the valid scientific evidence standard at 21 CFR 860.7, applied through the clinical data and analysis sections of a premarket approval application under 21 CFR 814.20 — where effectiveness evidence must consist principally of well-controlled investigations.

References

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. read 15 October 2026. View on EUR-LexThe regulation itself. Entered into force 26 May 2018 and applied from 26 May 2021. The Official Journal volume and page could not be opened and are not given. Note that UK legislation sites mark it revoked, which is UK retained-law status and not its status in the EU.
  2. Medical Device Coordination Group. MDCG 2020-6: Regulation (EU) 2017/745 — Clinical evidence needed for medical devices previously CE marked under Directives 93/42/EEC or 90/385/EEC. April 2020. read 15 October 2026. View on European CommissionQuotes Article 61(1) and the Annex XIV Part A provisions, which is how this site cites them, since the annex text itself could not be opened. Its Appendix I is also the authority on which parts of MEDDEV 2.7/1 rev. 4 remain relevant. Note that the Commission's index labels this document differently from its own title page; the title above is the document's own.
  3. Medical Device Coordination Group. MDCG 2020-13: Clinical evaluation assessment report template. July 2020. read 15 October 2026. View on European CommissionThe template a notified body uses to assess a clinical evaluation. The most useful public statement of what the clinical evaluation plan has to contain, because the assessor is told what to look for.
  4. Medical Device Coordination Group. MDCG 2020-5: Clinical Evaluation — Equivalence. A guide for manufacturers and notified bodies. April 2020. read 15 October 2026. View on European CommissionThe guidance on equivalence claims. It states that it is an MDCG document established under Article 103 of the MDR and is not a European Commission document, which is worth noting when citing it.
  5. European Commission. Guidance — MDCG endorsed documents and other guidance. Medical devices sector. read 15 October 2026. View on European CommissionThe Commission's own index of MDCG guidance. Note that it lists no MEDDEV document as a standalone entry, and that for at least one document its index label differs from the document's own title.
  6. International Council for Harmonisation. E3: Structure and Content of Clinical Study Reports. Step 4 version, 29 November 1995. FDA Guidance for Industry, July 1996. read 15 October 2026. View on U.S. Food and Drug AdministrationThe guideline that specifies what a clinical study report contains. Sixteen numbered sections. No revision of the guideline itself exists; whether a separate questions-and-answers addendum is current could not be confirmed, so none is claimed here.
  7. U.S. Food and Drug Administration. PMA Clinical Studies. Premarket Approval (PMA) guidance. read 15 October 2026. View on U.S. Food and Drug AdministrationThe US route has no document called a clinical evaluation report. The functional equivalent is the valid scientific evidence standard at 21 CFR 860.7 together with the clinical sections of a PMA under 21 CFR 814.20.

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s regulatory writing team prepares clinical evaluation plans and reports against Annex XIV and current MDCG guidance, including literature appraisal, equivalence justification where equivalence is available, and the post-market clinical follow-up documentation that keeps the report current. Responses to notified-body findings on an existing CER can be undertaken as a separate, defined piece of work within the agreed scope.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.